How viral infections affect people with chronic lung disease
Prospective Cohort Study to Understand Impact of Viral Infection in Chronic Lung Disease
Imperial College London · NCT06625944
This study will test if respiratory viruses trigger flare-ups and change immune responses in adults with COPD or bronchiectasis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Imperial College London (other) |
| Locations | 1 site (London) |
| Trial ID | NCT06625944 on ClinicalTrials.gov |
What this trial studies
Researchers will recruit adults with physician-confirmed chronic airway disease and follow them for up to two years, collecting samples when participants are well and again during flare-ups. Participants will provide self-collected nose swabs, finger-prick samples, and sputum at the start of an exacerbation and then attend a clinic visit for blood tests and further swabs. The prospective, closely monitored design aims to detect viruses early in exacerbations and compare viral presence and immune response between baseline and flare periods. Results are intended to clarify the role of respiratory viruses in driving exacerbations and inform future treatment strategies.
Who should consider this trial
Good fit: Adults with a physician-confirmed diagnosis of chronic airway disease (such as COPD or bronchiectasis) who have had at least one exacerbation in the past year and can complete daily symptom diaries and sample collection are ideal candidates.
Not a fit: People who are pregnant, unable to complete daily symptom diaries or attend follow-up visits, or who are clinically unstable or had an exacerbation within four weeks of recruitment are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this could identify viral causes of exacerbations and support earlier antiviral treatment strategies that reduce flare severity and unnecessary antibiotic use.
How similar studies have performed: Prior hospital-based and cross-sectional studies have linked viruses to exacerbations, but few prospective community-based cohorts with early sampling have been done, so this close-surveillance approach is only partially tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults with a physician confirmed diagnosis of chronic airway disease (e.g. COPD and bronchiectasis) according to established diagnostic criteria. AND \- Prior history of exacerbation within last year (defined as requiring antibiotic and/or corticosteroids). Exclusion Criteria: * Inability to complete daily symptom diaries and/or attend for clinical assessments. * Exacerbation within 4 weeks of study recruitment and/or clinical instability at the time of recruitment. * Pregnancy.
Where this trial is running
London
- Royal Brompton Hospital — London, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: Anand Shah — Imperial College London
- Study coordinator: Patrick Senior
- Email: senior.patrick@gmail.com
- Phone: 004402075895111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation, COPD, Respiratory Infection Virus, Natural Cohort, Prospective, Bronchiectasis, Chronic Lung Disease